Selective inhibition of the p53–MDM2 interaction by nutlin drugs: a new therapeutic perspective for neuroblastomaReport as inadecuate




Selective inhibition of the p53–MDM2 interaction by nutlin drugs: a new therapeutic perspective for neuroblastoma - Download this document for free, or read online. Document in PDF available to download.

(2013)PROCEEDINGS OF THE BELGIAN ROYAL ACADEMIES OF MEDICINE.2.p.198-207 Mark abstract Neuroblastoma is one of the most common and most deadly childhood tumors. There is an unmet need to develop new therapeutic modalities for this malignancy that preferentially should be guided by our increasing knowledge of the biology of neuroblastoma. Proliferation and survival of neuroblastoma cells is critically dependent on suppression of the activity of the tumor suppressor protein p53, which is often mediated by increased activity of the MDM2 oncoprotein. Accordingly, small-molecule inhibitors of the interaction between MDM2 and p53 may provide a useful therapeutic option for the treatment of neuroblastoma by restoring the potent antitumor activity of wild-type p53. One of the most promising classes of selective inhibitors of the p53–MDM2 interaction are the nutlins, which have been extensively studied over the last years in several tumor types, including neuroblastoma. We discuss here preclinical data that support the notion that nutlin drugs may offer therapeutic benefit for children with neuroblastoma, on condition that wild-type p53 is present.

Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-4228985



Author: Tom Van Maerken , Ali Rihani, Alan Van Goethem , Anne De Paepe , Franki Speleman and Jo Vandesompele

Source: https://biblio.ugent.be/publication/4228985



DOWNLOAD PDF




Related documents